Advanced Enzyme Technologies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 20.8x vs industry 54.7x)
- Virtually debt-free
- Regular dividends — yield 1.8%
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ADVENZYMES · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.62% | 43.50% | 43.02% | 42.95% | 42.92% | 43.08% |
| FII | 22.54% | 23.01% | 12.03% | 12.63% | 12.57% | 11.90% |
| DII | 6.98% | 7.56% | 8.08% | 8.02% | 8.17% | 8.19% |
| Public | 26.88% | 25.95% | 36.87% | 36.40% | 36.31% | 36.82% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 1.20 Per Share
Interim Dividend - Rs 4 Per Share
Record: 16 May 2025
Dividend - Re 1.1 Per Share
Interim Dividend - Rs 4 Per Share
Record: 17 May 2024
Dividend - Re 1 Per Share
Record: 4 Aug 2023
Interim Dividend - Rs 4 Per Share
Record: 19 May 2023
Latest News
All newsSun Pharma R&D arm announces new drug trials
*Sun Pharma R&D arm announces new drug trials.* The company approved initiation of Phase II clinical trials for **SPARC-021**, a novel dermatological compound. Board also approved **₹75 crore** funding for R&D expansion. This move strengthens its innovation pipeline in specialty dermatology. 📊 *STOCKS:* $SPARC | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #R&D
Sun Pharma Advanced Research reports Q1 FY26 results.
*Sun Pharma Advanced Research reports Q1 FY26 results.* The company has released its unaudited financial results for the quarter ended June 30, 2026. Key figures include revenue of **₹128.4 crore** and net profit of **₹22.1 crore**. Performance reflects steady growth in core R&D operations. 📊 *STOCKS:* $SPARC | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
TCS partners with Anthropic for enterprise AI solutions
*TCS partners with Anthropic for enterprise AI solutions*. TCS has launched a global premier partnership with AI firm Anthropic to scale enterprise AI solutions. The collaboration aims to deliver advanced AI-driven services to clients worldwide, boosting TCS's positioning in the AI space. This strategic move strengthens TCS’s AI capabilities and client offerings. 📊 *STOCKS:* TCS | 🏢 *SECTOR:* IT | #HIGHIMPACT #AI
Tata Group, Shapoorji Pallonji in talks for Tata Sons stake swap
*Tata Group and Shapoorji Pallonji are in advanced talks for a share swap involving a stake in Tata Sons.* The proposed deal could reshape ownership in the **₹25-lakh crore** conglomerate. Details including valuation and equity exchange are under discussion. Final terms may impact group stock valuations and investor sentiment. 📊 *STOCKS:* | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Tata
Persistent Systems eyes major acquisition
*Persistent Systems eyes major acquisition* — The IT firm is in advanced talks for a significant buyout, potentially exceeding ₹500Cr. This move signals aggressive expansion and vertical integration. A deal could boost scale and global delivery capabilities. 📊 *STOCKS:* PERSISTENT | 🏢 *SECTOR:* IT | #HIGHIMPACT #Acquisition
Tata Elxsi partners for India's first indigenous eVTOL aircraft
*Tata Elxsi partners for India's first indigenous eVTOL aircraft*. The company has partnered with Sarla Aviation to accelerate development of 'Shunya', India’s first homegrown electric vertical takeoff and landing aircraft. The collaboration marks a strategic move into advanced aviation tech. **No financial details** of the partnership were disclosed. 📊 *STOCKS:* $TATAELXSI | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #eVTOL
Creative Newtech partners with Jupiter Electric for drone tech expansion
*Creative Newtech partners with Jupiter Electric for drone tech expansion*. The company has entered into a strategic partnership to strengthen its drone technology portfolio. This collaboration aims to leverage Jupiter Electric Mobility’s expertise in electric systems for advanced drone solutions. The move signals a focused push into high-growth tech-driven applications. 📊 *STOCKS:* CREATIVENEW | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Partnership
Gabriel India partners with HL Klemove for autonomous driving tech
*Gabriel India partners with HL Klemove for autonomous driving tech.* The company has entered a strategic partnership with South Korea’s HL Klemove to co-develop advanced driver assistance systems (ADAS) and automotive electronics. This move accelerates Gabriel’s shift toward becoming a diversified mobility solutions provider. The collaboration aims to enhance product innovation in India’s evolving auto tech space. 📊 *STOCKS:* $GABRIEL | 🏢 *SECTOR:* Auto | #MEDIUMIMPACT #JointVenture
Natco Pharma invests in US biotech eGenesis Inc
*Natco Pharma invests in US biotech eGenesis Inc.* The company announced a strategic investment in eGenesis, Inc., a Massachusetts-based biotech firm, to explore cutting-edge biopharma opportunities. This move aims to strengthen Natco’s global footprint in advanced therapeutics. Financial details were not disclosed. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Investment
Sigma Advance Systems secures £125m Rolls-Royce deal post acquisition.
*Sigma Advance Systems secures £125m Rolls-Royce deal post acquisition.* The company has deepened its partnership with Rolls-Royce Aerospace UK through a long-term agreement worth **£125 million**. This follows Sigma's recent strategic acquisition of Bromford, enhancing its defence and aerospace capabilities. The deal strengthens its order book and global footprint in critical aerospace manufacturing. 📊 *STOCKS:* $SIGMA | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Aerospace
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹172 Cr 7.0% | ₹185 Cr 0.5% | ₹186 Cr 11.4% | ₹167 Cr 1.2% | ₹169 Cr 15.8% | ₹146 Cr 5.8% | ₹155 Cr 1.9% | ₹158 Cr |
| Op. Profit | ₹49 Cr 18.3% | ₹60 Cr 7.1% | ₹56 Cr 21.7% | ₹46 Cr 16.4% | ₹55 Cr 31.0% | ₹42 Cr 17.6% | ₹51 Cr 7.3% | ₹55 Cr |
| OPM | 29.0% 12.1% | 33.0% 10.0% | 30.0% 11.1% | 27.0% 18.2% | 33.0% 13.8% | 29.0% 12.1% | 33.0% 5.7% | 35.0% |
| Net Profit | ₹43 Cr 4.4% | ₹45 Cr 12.5% | ₹40 Cr 48.1% | ₹27 Cr 30.8% | ₹39 Cr 18.2% | ₹33 Cr 5.7% | ₹35 Cr 16.7% | ₹30 Cr |
| EPS (₹) | 3.8 1.8% | 3.87 8.4% | 3.57 50.6% | 2.37 29.7% | 3.37 14.6% | 2.94 3.6% | 3.05 20.6% | 2.53 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹746 Cr 17.1% | ₹637 Cr 2.1% | ₹624 Cr 15.3% | ₹541 Cr 2.3% | ₹529 Cr 5.4% | ₹502 Cr 13.1% | ₹444 Cr 5.7% | ₹420 Cr 7.4% | ₹391 Cr 18.8% | ₹329 Cr |
| Expenses | ₹517 Cr 17.2% | ₹441 Cr 5.5% | ₹418 Cr 9.4% | ₹382 Cr 16.8% | ₹327 Cr 21.6% | ₹269 Cr 11.6% | ₹241 Cr 2.1% | ₹236 Cr 4.4% | ₹226 Cr 27.7% | ₹177 Cr |
| Op. Profit | ₹229 Cr 16.8% | ₹196 Cr 4.9% | ₹206 Cr 30.4% | ₹158 Cr 22.2% | ₹203 Cr 12.5% | ₹232 Cr 14.3% | ₹203 Cr 10.3% | ₹184 Cr 11.5% | ₹165 Cr 8.6% | ₹152 Cr |
| OPM | 31.0% 0.0% | 31.0% 6.1% | 33.0% 13.8% | 29.0% 23.7% | 38.0% 17.4% | 46.0% 0.0% | 46.0% 4.5% | 44.0% 4.8% | 42.0% 8.7% | 46.0% |
| Other Income | ₹46 Cr 39.4% | ₹33 Cr 57.1% | ₹21 Cr 0.0% | ₹21 Cr 250.0% | ₹6 Cr 33.3% | ₹9 Cr 50.0% | ₹6 Cr 20.0% | ₹5 Cr 400.0% | ₹1 Cr 66.7% | ₹3 Cr |
| Interest | ₹3 Cr 40.0% | ₹5 Cr 25.0% | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 20.0% | ₹5 Cr 44.4% | ₹9 Cr 125.0% | ₹4 Cr |
| Depreciation | ₹40 Cr 8.1% | ₹37 Cr 5.7% | ₹35 Cr 0.0% | ₹35 Cr 0.0% | ₹35 Cr 25.0% | ₹28 Cr 7.7% | ₹26 Cr 23.8% | ₹21 Cr 16.7% | ₹18 Cr 38.5% | ₹13 Cr |
| PBT | ₹233 Cr 24.6% | ₹187 Cr 0.5% | ₹188 Cr 34.3% | ₹140 Cr 18.1% | ₹171 Cr 18.6% | ₹210 Cr 17.3% | ₹179 Cr 10.5% | ₹162 Cr 16.5% | ₹139 Cr 1.5% | ₹137 Cr |
| Tax % | 25.0% 10.7% | 28.0% 3.7% | 27.0% 3.8% | 26.0% 7.1% | 28.0% 0.0% | 28.0% 7.7% | 26.0% 7.1% | 28.0% 15.2% | 33.0% 3.1% | 32.0% |
| Net Profit | ₹174 Cr 29.9% | ₹134 Cr 2.2% | ₹137 Cr 31.7% | ₹104 Cr 16.1% | ₹124 Cr 17.9% | ₹151 Cr 13.5% | ₹133 Cr 14.7% | ₹116 Cr 23.4% | ₹94 Cr 1.1% | ₹93 Cr |
| EPS (₹) | 15.07 28.6% | 11.72 1.7% | 11.92 26.1% | 9.45 11.7% | 10.7 18.3% | 13.09 13.0% | 11.58 16.4% | 9.95 23.3% | 8.07 1.6% | 8.2 |
| Div Payout | 9.0% 79.5% | 44.0% 2.3% | 43.0% 290.9% | 11.0% 22.2% | 9.0% 28.6% | 7.0% 40.0% | 5.0% 16.7% | 6.0% 0.0% | 6.0% 20.0% | 5.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr |
| Reserves | ₹1.5K Cr 4.6% | ₹1.4K Cr 7.4% | ₹1.3K Cr 7.3% | ₹1.2K Cr 13.8% | ₹1.1K Cr 12.4% | ₹948 Cr 16.0% | ₹817 Cr 24.4% | ₹657 Cr 22.3% | ₹537 Cr 21.5% | ₹442 Cr |
| Borrowings | ₹35 Cr 10.3% | ₹39 Cr 17.0% | ₹47 Cr 38.2% | ₹34 Cr 2.9% | ₹35 Cr 52.2% | ₹23 Cr 17.9% | ₹28 Cr 20.0% | ₹35 Cr 47.8% | ₹67 Cr 24.1% | ₹54 Cr |
| Other Liabilities | ₹173 Cr 14.6% | ₹151 Cr 0.7% | ₹150 Cr 5.6% | ₹142 Cr 3.6% | ₹137 Cr 10.5% | ₹153 Cr 47.1% | ₹104 Cr 14.3% | ₹91 Cr 10.8% | ₹102 Cr 56.9% | ₹65 Cr |
| Total Liabilities | ₹1.7K Cr 5.0% | ₹1.6K Cr 5.9% | ₹1.5K Cr 7.8% | ₹1.4K Cr 12.0% | ₹1.3K Cr 9.9% | ₹1.1K Cr 18.0% | ₹971 Cr 20.6% | ₹805 Cr 10.7% | ₹727 Cr 24.7% | ₹583 Cr |
Assets | ||||||||||
| Fixed Assets | ₹683 Cr 0.6% | ₹679 Cr 4.5% | ₹650 Cr 0.2% | ₹649 Cr 4.8% | ₹619 Cr 3.0% | ₹601 Cr 6.7% | ₹563 Cr 13.7% | ₹495 Cr 0.8% | ₹491 Cr 16.6% | ₹421 Cr |
| CWIP | ₹31 Cr 40.9% | ₹22 Cr 46.3% | ₹41 Cr 86.4% | ₹22 Cr 46.7% | ₹15 Cr 50.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 9.1% | ₹11 Cr 37.5% | ₹8 Cr |
| Investments | ₹529 Cr 10.2% | ₹480 Cr 19.1% | ₹403 Cr 11.9% | ₹360 Cr 252.9% | ₹102 Cr 15.7% | ₹121 Cr 2.4% | ₹124 Cr 11.7% | ₹111 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹449 Cr 4.4% | ₹430 Cr 0.7% | ₹427 Cr 12.4% | ₹380 Cr 27.5% | ₹524 Cr 26.9% | ₹413 Cr 50.2% | ₹275 Cr 46.3% | ₹188 Cr 16.8% | ₹226 Cr 47.7% | ₹153 Cr |
| Total Assets | ₹1.7K Cr 5.0% | ₹1.6K Cr 5.9% | ₹1.5K Cr 7.8% | ₹1.4K Cr 12.0% | ₹1.3K Cr 9.9% | ₹1.1K Cr 18.0% | ₹971 Cr 20.6% | ₹805 Cr 10.7% | ₹727 Cr 24.7% | ₹583 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹142 Cr 0.7% | ₹141 Cr 0.7% | ₹140 Cr 14.8% | ₹122 Cr 25.2% | ₹163 Cr 15.6% | ₹141 Cr 9.3% | ₹129 Cr 11.2% | ₹116 Cr 8.4% | ₹107 Cr 15.1% | ₹93 Cr |
| Investing CF | ₹-89 Cr 36.9% | ₹-65 Cr 77.3% | ₹-286 Cr 14400.0% | ₹2 Cr 107.4% | ₹-27 Cr 37.2% | ₹-43 Cr 65.3% | ₹-124 Cr 106.7% | ₹-60 Cr 0.0% | ₹-60 Cr 500.0% | ₹-10 Cr |
| Financing CF | ₹-73 Cr 23.7% | ₹-59 Cr 126.9% | ₹-26 Cr 45.8% | ₹-48 Cr 84.6% | ₹-26 Cr 33.3% | ₹-39 Cr 9.3% | ₹-43 Cr 2050.0% | ₹-2 Cr 96.9% | ₹-65 Cr 3.2% | ₹-63 Cr |
| Net Cash Flow | ₹-20 Cr 217.6% | ₹17 Cr 109.9% | ₹-171 Cr 328.0% | ₹75 Cr 31.2% | ₹109 Cr 81.7% | ₹60 Cr 257.9% | ₹-38 Cr 170.4% | ₹54 Cr 400.0% | ₹-18 Cr 185.7% | ₹21 Cr |
| Free Cash Flow | ₹108 Cr 14.9% | ₹94 Cr 7.8% | ₹102 Cr 7.4% | ₹95 Cr 33.6% | ₹143 Cr 58.9% | ₹90 Cr 22.4% | ₹116 Cr 10.5% | ₹105 Cr 8.2% | ₹97 Cr 10.2% | ₹88 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66d 13.8% | 58d 14.7% | 68d 11.5% | 61d 3.2% | 63d 3.3% | 61d 19.6% | 51d 7.3% | 55d 0.0% | 55d 5.8% | 52d |
| Inventory Days | 378d 0.8% | 375d 9.3% | 343d 14.7% | 402d 16.2% | 346d 4.2% | 361d 0.6% | 363d 7.1% | 339d 3.7% | 352d 1.7% | 358d |
| Days Payable | 41d 2.5% | 40d 40.3% | 67d 11.7% | 60d 7.1% | 56d 30.2% | 43d 6.5% | 46d 41.0% | 78d 36.8% | 57d 16.2% | 68d |
| Cash Conv. Cycle | 403d 2.5% | 393d 14.2% | 344d 14.9% | 404d 14.4% | 353d 6.9% | 379d 2.7% | 369d 17.1% | 315d 10.3% | 351d 2.6% | 342d |
| Working Capital Days | 112d 9.8% | 102d 6.4% | 109d 6.0% | 116d 23.4% | 94d 4.4% | 90d 25.0% | 72d 53.2% | 47d 38.2% | 76d 2433.3% | 3d |
| ROCE | 13.0% 13.3% | 15.0% 25.0% | 12.0% 25.0% | 16.0% 27.3% | 22.0% 0.0% | 22.0% 8.3% | 24.0% 4.0% | 25.0% 19.4% | 31.0% 13.9% | 36.0% |
Source: Screener.in · Lower days = better efficiency
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
HealthcarePharmaceuticals & Biotechnology